insights_auto
Why is EDIT down 11.75%?
Dive Deeperchevron_right
EDIT:NASDAQ
Editas Medicine Inc
$1.92
arrow_downward
-11.75%(-0.26) 1D
Nov 16, 2:37:13 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
$2.10
High
$2.12
Low
$1.90
Mkt. cap
295.56M
Avg. vol.
2.44M
Volume
1.29M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
154.34M
No. of employees
87
Open
$2.10
High
$2.12
Low
$1.90
Mkt. cap
295.56M
Avg. vol.
2.44M
Volume
1.29M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
154.34M
No. of employees
87
News stories
From web sources and news partners
Investor's Business Daily
·
27 minutes ago
Tyson, Starbucks Lead The S&P 500, Nasdaq 100 As Investors Play Defense
The Motley Fool
·
1 hour ago
McDonald's Is Underperforming the S&P 500 and Nasdaq-100. Could January Mark a Turning Point?
Yahoo Finance
·
20 minutes ago
The S&P 500’s shot at 4 straight double-digit years is in Nvidia’s hands
The Korea Times
·
1 hour ago
Nasdaq, S&P 500 fall over 1% in run-up to Nvidia results, Anthropic debut
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company that is developing therapies for rare diseases using CRISPR gene editing technology. Editas Medicine headquarters is located in Cambridge, Massachusetts with additional facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
FoundedNov 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteeditasmedicine.com